<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003867/" ref="ordinalpos=2763&amp;ncbi_uid=6068200&amp;link_uid=PMC4003867" image-link="/pmc/articles/PMC4003867/figure/F1/" class="imagepopup">Figure 1. <span class="highlight" style="background-color:">Signaling</span> pathways of IL-22.  From: Emerging role of Interleukin-22 in autoimmune diseases. </a></div><br /><div class="p4l_captionBody">IL-22 binds as a homodimer at a receptor complex composed of the IL-10R2 and the IL-22R1. IL-22BPacts as a natural, soluble antagonist. Receptor signaling induces the phosphorylation of Jak-1 and Tyk-2, which activates the transcription factor STAT1, and depending on the cell type, also STAT3 and STAT5. MAPKpathway (including MEK1/2, ERK1/2, JNK, and p38) are also activated through a distinct pathway.</div></div>